晚期复发性卵巢上皮性癌的再治疗

目的 :探讨晚期复发性卵巢上皮癌再治疗的方法。方法 :回顾性分析 1996- 2 0 0 1年住院治疗的晚期复发性卵巢癌病例共 5 6例临床资料。卵巢浆液性癌 2 6例 ,黏液性癌 19例 ,宫内膜样癌 10例 ,转移性腺癌 1例。基本治疗原则仍是以手术为主联合术前术后的化疗。结果 :截至 2 0 0 2年 5月全部随访 ,死亡 2 3例 ,现存活 33例。已死亡者平均生存时间为 18 5个月。总的 3年生存率为 2 7 5 % ( 6/ 2 2 ) ,其中泰素类用药组为 4 / 12。拓扑替康组共 8例 ,其有效率为 3/ 8。结论 :1)紫杉醇 +顺铂的联合化疗可成为晚期复发性卵巢癌再治疗的首选。 2 )拓扑替康联合化疗是复发性卵巢癌有效的补救治疗手段 ,值得推广应用。 3)再次手术治疗仍是晚期复发性卵巢癌重要的治疗手段之一

Secondary Therapy of Advanced Palindromic Ovarian Epithelial Carcinoma

Objctive To study the method of secondary therapy in patients with advanced palindromic ovarian epithelial carcinoma.Methods The clinical data of 56 patients with advanced palindromic ovarian epithelial carcinoma hospitalized from 1996 to 2001 were reviewed and analyzed retrospectively,including 26 serous carcinoma,19 mucinous carcinoma,10 endometriod carcinoma and 1 metastatic adenocarcinoma.Operation combined with preoperative and postoperative chemotherapy was the primary therapeutic principle.Results By May 2002,23 women were dead,33 were survival.The mean survival time was 18.5 months while the overall 3-year survival rate was 27.5%(6/22),including 4(4/12) cases treated with taxol and 8 cases with topotecan whose effective rate was 3/8.Conclusions 1)The combined chemotherapy with TP regimen (Taxol+DDP) is the first-line treatment in advanced palindromic ovarian epithelial carcinoma.2)The combination chemotherapy with toptecan is a prospective method,which is the effective remedial therapy.3)The reoperation is still the significant therapeutic method in advanced palindromic ovarian epithelial carcinoma.